Companies to Watch – Elegen In the last of four features on Elegen, we present a case study of how Elegen’s cell-free ENFINIA™ DNA accelerates projects with high sequence complexity from the drawing board to the incubator, saving weeks to advance research goals faster. Download the case study here This is […]
elegen
Elegen’s Cell-Free DNA Synthesis Speeds the Discovery and Development of Genetic Medicines
/ big4bio
Company to Watch – Elegen In the third of four features on Elegen, Marc Unger, Chief Scientific Officer, talks about Elegen’s cell-free DNA synthesis technology ENFINIA DNA, how it changes the paradigm of discovery and development for genetic medicines, and the company’s recent collaboration with GSK. In the final feature, Elegen will present a case […]
Podcast: Solving Major Bottlenecks in Genetic Medicine and SynBio With DNA Synthesis Innovation
/ big4bio
Company to Watch – Elegen The Big4Bio Podcast · Addressing the Bottleneck in DNA Synthesis As part of April 2024’s Company to Watch program, we speak to Matt Hill, founder and CEO of Elegen, about Elegen’s ENFINIA DNA technology, the need it addresses, and how it has disrupted the status quo for DNA synthesis. […]
Removing Bottlenecks in Synthetic Biology with Cell-Free Synthesis of Long and Complex DNA
/ big4bio
Companies to Watch – Elegen In the first of four features on Elegen, Randy Dyer, vice president of marketing, talks about the spark behind the formation of the company as well as its mission to unlock the promise of synthetic biology by eliminating a critical bottleneck in the supply of synthetic DNA for genetic medicine […]